New
Stock Market Roundup 2024: Here's What Worked, What Didn't, And What Stocks Investors Can Buy Now And Hold Forever
The start of a new year is a great time to review what happened over the last 12 months and take some lessons from it.
So, as 2025 gets underway, let's take a quick look back to see the highlights and lowlights from 2024 -- and what could be in store for the year ahead.
Start Your Mornings Smarter! Wake up with Breakfast news in your inbox every market day. Sign Up For Free »
Image source: Getty Images.
The best of the best
Without a doubt, one of the biggest investing themes of 2024 was artificial intelligence (AI) stocks.
Nvidia (NASDAQ: NVDA), the king of AI stocks, battled Apple in a struggle to claim the title of the world's largest public company by market cap. As of this writing, Nvidia has once again surpassed the iPhone maker to claim the top spot, albeit by the narrowest of margins.
However, 2024 saw many other AI stocks surge, too. Palantir Technologies' stock soared by a remarkable 341%; SoundHound AI's stock advanced an eye-popping 836%.
It wasn't just the pure-play AI stocks that benefited last year. Overall, it was a big year for big tech.
Meta Platforms, Amazon (NASDAQ: AMZN), Alphabet, and Apple all outperformed the S&P 500 in 2024. Only Microsoft lagged the benchmark index.
META Total Return Level data by YCharts
In short, thanks to the continued unfolding of the AI boom, technology was a great place to invest in 2024.
The worst of the worst
If there was one sector that just didn't work for investors in 2024, it was budget retailers/convenience pharmacies.
Walgreens Boots Alliance, Dollar Tree, Dollar General, and CVS Health were among the worst-performing stocks in 2024. Each of them declined by at least 40% for the year, with Walgreens losing more than 60% of its value.
WBA Total Return Level data by YCharts
The effects of inflation took a toll on all of these companies as consumers cut back on purchases. As for the pharmacy retailers, falling reimbursement rates for drugs, increased theft, and rising competition sent shares tumbling.
Running a close second to the budget retailers were certain healthcare stocks. In particular, Moderna and Biogen. Moderna suffered a prolonged hangover as demand for COVID-19 vaccines fell. Shares of the vaccine maker tumbled by more than 57%. Biogen, on the other hand, has various problems that contributed to its 41% sell-off. Sales of its key Alzheimer's drug have slowed, and there are concerns that the company's drug pipeline is weak, meaning future revenue could come under pressure.
To sum up, discount retailers, convenience pharmacies, and certain drugmakers were the big losers in 2024.
What I'm excited to buy (and hold forever) in 2025
As has been the case for many years, I currently prefer growth stocks to value stocks. In particular, the tech sector remains a favorite of mine.
However, surveying the tech landscape at the start of 2025, three stocks stand out as companies that I want to buy and hold forever:
- Nvidia
- Amazon
- Tesla (NASDAQ: TSLA)
Nvidia makes the cut because it remains the primary beneficiary of the AI boom. While Nvidia's competitive advantage will eventually fade, there are no signs of it happening anytime soon. The company still designs the best AI chips, and demand for its products remains red-hot. In turn, the company is growing revenue and profits at a breakneck pace. In short, it remains all systems go for Nvidia as 2025 gets under way.
As for Amazon, I'm a longtime believer (and shareholder) in the company. As I've noted before, Amazon is best viewed as a conglomerate rather than simply an e-commerce company. Amazon Web Services (AWS) now generates over $100 billion in revenue per year, making it a giant in its own right if it were ever spun off into its own company. As for e-commerce, Amazon is growing its profitability through innovations like robotics, which drive down costs and shorten delivery times to consumers.
Finally, there's Tesla. Similar to Amazon, I believe investors need to adjust how they think of Tesla. True, automotive sales still make up a huge share of the company's revenue, but, increasingly, Tesla is becoming a robotics company. As its autonomous driving software (FSD) improves, Tesla's true value could be unlocked, as the company expands into ride-sharing, autonomous deliveries, and futuristic applications we haven't even considered. That's to say nothing of the company's Optimus robot, which could provide another revenue stream. To sum up, Tesla's future still looks bright as we step into 2025 -- making it one of my top choices as a stock to buy and hold forever.
Don’t miss this second chance at a potentially lucrative opportunity
Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.
On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:
- Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $363,307!*
- Apple: if you invested $1,000 when we doubled down in 2008, you’d have $45,963!*
- Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $471,880!*
Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.
*Stock Advisor returns as of January 6, 2025
Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Jake Lerch has positions in Alphabet, Amazon, Nvidia, and Tesla. The Motley Fool has positions in and recommends Alphabet, Amazon, Apple, Meta Platforms, Microsoft, Nvidia, Palantir Technologies, and Tesla. The Motley Fool recommends Biogen, CVS Health, and Moderna and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
